MedTrace Logo

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants

NCT05751642 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-11-27

No results posted yet for this study

Summary

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single ascending doses (SADs) of ALXN1920 subcutaneous (SC) and of a single dose of ALXN1920 intravenous (IV) in healthy adult participants.

Conditions

  • Healthy Participants

Interventions

BIOLOGICAL

ALXN1920

Participants will receive a single dose of ALXN1920 by Subcutaneous (SC) injection.

BIOLOGICAL

Placebo

Participants will receive a single dose of Placebo by SC injection, SC infusion or IV infusion.

BIOLOGICAL

ALXN1920

Participants will receive a single dose of ALXN1920 by SC infusion.

BIOLOGICAL

ALXN1920

Participants will receive a single dose of ALXN1920 by Intravenous (IV) infusion.

Sponsors & Collaborators

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-19
Primary Completion
2023-12-04
Completion
2023-12-04

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05751642 on ClinicalTrials.gov